FilingIndex
8-KThe WireRoutine

Shareholder Vote

Filed May 31, 2019 · 7y ago · Accession 0001437749-19-011113

Plain English

Material event — a significant development the company must disclose promptly.

Read the source below for the full document.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2019 National Research Corporation (Exact name of registrant as specified in its charter) Wisconsin 0 01 - 35929 47-0634000 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1245 Q Street, Lincoln, Nebraska 68508 (Address of principal executive offices, including zip code) (402) 475-2525 (Registrant’s telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.001 par value NRC The NASDAQ stock market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ -1- Item 5.07 . Submission of Matters to a Vote of Security Holders . On May 29, 2019, National Research Corporation (the “Company”) held its 2019 annual meeting of shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on the following proposals: ● The election of one director, Donald M. Berwick, to the Company’s Board of Directors for a three-year term to expire at the Company’s 2022 annual meeting of shareholders; ● The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for 2019; and ● An advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement. As of the March 22, 2019 record date for the determination of the shareholders entitled to notice of, and to vote at, the Annual Meeting, 24,864,391 shares of the Company’s common stock were outstanding and eligible to vote. Approximately 98.21% of all shares (and votes) were represented at the Annual Meeting in person or by proxy. The following are the final votes on the matters presented for shareholder consideration at the Annual Meeting: Election of Directors The shareholders elected Donald M. Berwick as a director for a three-year term to expire at the Company’s 2022 annual meeting of shareholders. The results of the vote were as follows: For Withheld Broker Non-Votes Name Votes Percentage (1) Votes Percentage Votes Percentage (2) Donald M. Berwick 22,819,437 98.45% 359,568 1.55% 1,240,824 N/A Ratify Appointment of KPMG LLP for 2019 The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for 2019. The results of the vote were as follows: For Against Abstain Broker Non-Votes Votes Percentage (1) Votes Percentage (1) Votes Percentage ( 2 ) Votes Percentage (2) 24,278,169 99.90 % 23,891 0.10 % 117,769 N/A 0 N/A Advisory Vote to Approve Executive Compensation The shareholders approved the compensation of the Company’s named executive officers as disclosed in the proxy statement. The results of the advisory vote were as follows: For Against Abstain Broker Non-Votes Votes Percentage (1) Votes Percentage (1) Votes Percentage ( 2 ) Votes Percentage (2) 23,084,786 99.90 % 22,568 0.10 % 71,651 N/A 1,240,824 N/A (1) Based on a total of all votes received and eligible to be counted as voted on this proposal at the Annual Meeting. (2) “N/A” means that abstentions and/or broker non-votes do not have any effect on the voting results on this proposal. -2- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 31, 2019 NATIONAL RESEARCH CORPORATION By: /s/ Kevin R. Karas Kevin R. Karas Senior Vice President Finance, Chief Financial Officer, Treasurer and Secretary -3-
Filing details
Company
NRC HEALTH
Ticker
NRC
CIK
70487
Form type
8-K
Filing date
May 31, 2019
Report date
May 29, 2019
Document
nrc20190530_8k.htm
Size
53 KB